Short- and long-term safety of oral propranolol in the treatment of infantile hemangioma

Infantile hemangioma is the most common tumor in infancy, with an incidence of 4% - 5%. According to the risk level, hemangioma is divided into 3 levels: high risk, medium risk and low risk. At present, the first-line treatment of high-risk hemangioma is oral propranolol (β-receptor blockers) . It has been 10 years since infantile hemangioma was treated with propranolol for the first time, and propranolol has been the drug of first-choice in systematic treatment due to its high efficacy and good safety, but its long-term adverse effect needs further evaluation. Key words: Hemangioma; Propranolol; Infant; Long-term safety; Short-term safety